Company registration number: 05174065 Charity registration number: 1107539 Charity number (Scotland): SC049810
## The Aplastic Anaemia Trust
(A company limited by guarantee)
Annual Report and Financial Statements for the Year Ended 31 March 2022
KM Chartered Accountants 1st Floor, Block C The Wharf Manchester Road Burnley Lancashire BB11 1JG
## **The Aplastic Anaemia Trust**
## **Contents**
|Reference and Administrative Details|1|
|---|---|
|Trustees' Report|2 to 8|
|Independent Examiner's Report|9|
|Statement of Financial Activities|10|
|Balance Sheet|11|
|Notes to the Financial Statements|12 to 18|
## **The Aplastic Anaemia Trust**
|**Reference and Administrative Details**|**Reference and Administrative Details**|
|---|---|
|**Chair**|A Conquy|
|**Trustees**|A Conquy|
||P M Cossell|
||J L Cozens|
||S Moos|
||T Stephenson|
|**Secretary**|S L Tyler|
|**Principal Office**|1st Floor, Block C|
||The Wharf|
||Manchester Road|
||Burnley|
||Lancashire|
||BB11 1JG|
|**Company Registration Number**|05174065|
|**Charity Registration Number**|1107539|
|**Charity Registration Number**|SC049810|
|**Scotland**||
|**Bankers**|CAF Bank Ltd|
||25 Kings Hill Avenue|
||Kings Hill|
||West Malling|
||Kent|
||ME19 5JQ|
|**Independent Examiner**|KM|
||Chartered Accountants|
||1st Floor, Block C|
||The Wharf|
||Manchester Road|
||Burnley|
||Lancashire|
||BB11 1JG|
Page 1
## **The Aplastic Anaemia Trust**
## **Trustees' Report**
The trustees, who are directors for the purposes of company law, present the annual report together with the financial statements of the charitable company for the year ended 31 March 2022.
## **Trustees**
A Conquy
P M Cossell
J L Cozens
Prof P H Hillmen (resigned 3 February 2022)
Prof J C W Marsh (resigned 3 February 2022)
S Moos
Prof G M Mufti (resigned 3 February 2022) Dr S R Samarasinghe (resigned 3 February 2022)
T Stephenson
## **Introduction**
As reported last year, 2020-2021 saw the range and depth of our community work fundraising and communications grow and 2021- 2022 has been a very significant year of consolidation of that work.
The Aplastic Anaemia Trust (AAT) is fortunate to have such a dynamic and professional team, headed by our CEO, Stevie Tyler. Their work around developing the detail of our strategy, combined with broadening our relationships, alliances and strategic partnerships has meant that the charity achieves positive impacts, exceeding expectations for a charity of our size and we are proud we can serve our community in an increasingly impactful way. It has been a particularly strong year for fundraising, with events and community fundraising bouncing back and a strong focus on stewardship.
Although Covid has been always in the frame impacting the health of patients with aplastic anaema as well as our own team, we have been able continue to grow our reach by keeping our support and outreach largely online. Throughout, our clear focus has been on developing our relationships with our community, ensuring we meet their needs and retain their loyalty and good will through strong supporter experience and increasingly thorough data collection.
Another focus has been governance. We began the process of reconfiguring and strengthening our Board, informed by a skills audit, alongside the development of a new Research and Clinical Advisory panel comprising 11 leading clinicians and researchers working in the field of aplastic anaemia whose guidance will be every more invaluable to the staff and the board regarding our investments in research as well as the needs of people with aplastic anaemia and their families. The charity is indebted to them for their knowledge and experience as well their generous support and advice.
Thank you to everyone in our community, and to our supporters, volunteers, and donors for their incredible efforts in fundraising and growing the awareness of aplastic anaemia. And equal thanks to the Aplastic Anaemia Trust’s staff and to Stevie Tyler for their dedication, imagination and skilful persistence, as well as their expertise. Finally, our thanks to the trustees on the board for their support.
We hope that you will see in the following pages of our Annual Report the extent to which our pledge to continue to help fight aplastic anaemia and help those who live with it is stronger than ever.
Page 2
## **The Aplastic Anaemia Trust**
## **Trustees' Report**
## **What is Aplastic Anaemia?**
**Aplastic anaemia** (AA) is a rare and life-threatening form of bone marrow failure. Most cases are acquired. However inherited types of AA are also quite common and can present in adults, not just in children.
The Aplastic Anaemia Trust is the only UK charity working at grassroots to support every aplastic anaemia sufferer and their loved ones and to help relieve the immense disease burden.
## **Our Mission, Vision and Objectives**
The objects of the charity as defined in its Articles of Association are to relieve the sickness of those people suffering from bone marrow disease and immune defects.
## **Vision**
Everyone affected by aplastic anaemia in the UK should feel empowered, and have access to the best possible treatment, care and support. And one day, everyone with rare bone marrow failure will be able to lead a full and healthy life.
## **Mission**
We deliver our vision though two key strategies:
• Enabling research into aplastic anaemia and other rare bone marrow failures to understand the cause, improve treatments and eventually eradicate it altogether.
• Empowering people affected by aplastic anaemia to lead healthy and fulfilling lives through support, advocacy and improvements to health and social care systems.
## **Our strategic objectives**
A. Ensure everyone affected by AA has the informational, practical, and emotional support they need to lead healthy and fulfilling lives.
B. Improve the knowledge and understanding of AA through education, campaigning, community outreach, leveraging partnerships, advocacy, and system change.
C. Enable ground-breaking research partnerships which lead to improved treatments and better outcomes. D. Underpinning the above, build and hold an evidence base on our community, their experiences and the needs they have.
Our fundraising acts as an enabler in our strategy, ensuring we have the resources to deliver these objectives.
## **The challenges we worked hard to address in 2021/22**
• Delivering a whole calendar of in-person fundraising and community events for the first time with the CEO and fundraising team in place
• Developing a robust income and expenditure plan for the next three years, ensuring a sustainable organisation.
## **AAT’s achievements and performance highlights for public benefit in 2021/2022**
The Board of Trustees confirm they have had regard to the Charity Commission's guidance on public benefit and have complied with their duty under section 4 of the Charities Act 2011 when reviewing the charity's aims and objectives and in implementing current and planning future activities.
In line with the governing document, the Memorandum and Articles of Association, our performance highlights for the last year in relation to the Charity's aims are set out below.
Page 3
## **The Aplastic Anaemia Trust**
## **Trustees' Report**
## **1. Adult patient information, outreach and support**
## **COVID Ongoing**
The continuing COVID-19 pandemic has been a significant concern for our community this year, with many community members experiencing issues accessing booster vaccinations, monoclonal antibody and antiviral treatments, and more significantly, feeling unsure what to do to keep themselves safe at points during the year where wider restrictions, and support mechanisms for people who are clinically extremely vulnerable were relaxed, or withdrawn completely.
To ensure that our community were able to access reliable, accurate and relevant information about matters concerning COVID-19, we continually revised our website with the latest updates relating to vaccinations, changes to shielding guidelines and access to treatments. In cases where our community reported issues, such as with accessing booster vaccinations, or treatments in cases where they tested positive for COVID-19, we advocated for our community, developing resources for them to advocate their need for vaccinations or treatment, and fed back their concerns to the Department for Health through our partners, including the Specialised Health Care Alliance and the Blood Cancer UK Vaccine Taskforce.
Throughout the year, we saw an ever-increasing demand for support across all channels, including our Helpline, private Facebook group and website. COVID-19-related enquiries accounted for more than twenty per-cent of all of the issues that we supported members of our community with.
## **Newly diagnosed patients**
We also observed a significant increase in the number of newly diagnosed people approaching us for support this year. Almost 20% of all enquiries to our support service were from people, or the families of people, who were newly diagnosed with aplastic anaemia. We believe that this may be reflective of wider pressures in the NHS, such as people experiencing delays in receiving a formal diagnosis, or accessing specialist support.
## **Winter Isolation**
Over the winter months of 2020, many of our community members reported that they felt isolated during the times that the UK was in lockdown, which had a detrimental impact on their mental wellbeing. Keen to prepare for this, we developed a programme of online wellbeing events, taking place between October and March, to develop cohesion amongst our community who may have been isolating, and equip them with practical skills and techniques to maintain their wellbeing. We facilitated a wide range of events, ranging from meditation to expert-led webinars exploring themes such as ‘managing uncertainty’ and ‘managing fatigue’, all key issues which can be a significant burden for people affected by aplastic anaemia.
## **2. Paediatric patient information, outreach support**
Our key focus in paediatric work this year has been the creation and development of The Aplastic Anaemia Trust Youth Board.
The six-month Youth Board Pilot saw 10 young people affected by aplastic anaemia take a new role in learning about and advising on the way our charity operates.
Some notable successes of the Youth Board during our six-month pilot were:
Page 4
## **The Aplastic Anaemia Trust**
## **Trustees' Report**
- Creating a Tough Mudder fundraising team
- Instigating a rehabilitation project for young people in treatment for AA - The AAT is now in talks with CAN Rehab about launching a pilot project
- The AA Voices Film Project, which is running in partnership with Fully Focussed to empower four young
- people affected by AA to tell their stories through film
- Members providing valuable feedback on the MarrowKidz project and others, to report back to funders and
- inform the next phase of our work for young people
- Contacts at The National Lottery Community Fund commented on how impressed they are by the Youth
- Board, and how its existence could make The AAT more likely to receive support in the future
- The Youth Boad advised the Support and Outreach team to send cards and gifts to children with AA in
- isolation at Christmas, because this is an especially hard time for children and young people.
- Youth Board Members provided important services for the charity through volunteering opportunities,
- including making befriending phone calls and producing a new resource about AA for Maggie's centre heads.
- Members have widened their understanding of how the charity is run - from the finances and funding to
- supporting people
• Bringing members together for peer support was a key benefit of the Youth Board. Elin said " _Knowing the meetings are coming up, it was nice to speak to people who know what we’re going through. You don’t have to explain yourself, everyone just knows."_
Following the successful Pilot, the Youth Board was evaluated to relaunch in April 2023, with a new round of recruitment and ambitious plans to engage a wider group of young people and strengthen the Youth Board’s relationship with the Board of Trustees.
## **3. Research**
The AAT is currently committed to funding three important research projects, to progress treatments of aplastic anaemia and to further the understanding of the disease.
**a. Identification and relevance of novel somatic mutations in patients with aplastic anaemia** , led by Dr Alex Smith and Professor Ghulam Mufti, King’s College Hospital, London
## In summary:
Clonal evolution, in recovering bone marrow, following immunosuppressive treatment in AA has important clinical and prognostic implications.
## Update:
Since our seminal paper in the journal Blood, others have reported similar outcomes - and is now an active area of interest and research being prospectively carried out by various centres. We continue with long term follow-up of patients enrolled in the EBMT sponsored RACE study, to determine emergence and patterns of mutation (co-exist, symbiotic or attritional) and its correlation with disease relapse and evolution. We have now further refined our next generation sequencing (NGS) to detect these mutations to 44 genes (commonly associated with myeloid disorders).
In addition, our CHIP study (Clonal haematopoiesis of indeterminate potential) serves as a useful comparator group.
We continue to receive samples and monitor patients in this study and will look forward to presenting results/publications in due course.
Page 5
## **The Aplastic Anaemia Trust**
## **Trustees' Report**
**b. Establishment of a paediatric UK bone marrow failure registry and biobank** , led by Dr Sujith Samarasinghe, Great Ormond Street Hospital, London
This project is moving into its final year, after which we anticipate the publication of a research paper sharing the results of this project.
GOSH and the AAT are working together to create a funding proposal to expand the registry over a ten-year period.
**c. Production of expanded autologous regulatory T cells to treat patients with refractory aplastic anaemia in a phase I dose study** , led by Professor Ghulam Mufti, King’s College Hospital, London
Progress headlines:
After delays due to covid and Brexit, recruitment for this trial begins in Summer 2022.
## **4. Fundraising**
2021/22 was a very strong fundraising year for us, raising in excess of £210,000 against a predicted £165,000. This was due to a strong community and events calendar and excellent stewardship of our supporters. The third year of our annual campaign Super Rare, culminating in Aplastic Anaemia Awareness Day, also helped give focus to our fundraising. In addition, our Pharma relationships enabled us to deliver our Winter Wellbeing programme and raised £60,000 towards our target to support it.
## **5. Awareness and strategic capacity**
The primary goals of our awareness-raising in 2021/22 were to bring a sense of community and joy to people who were still feeling isolated and unsure about socialising two years into a pandemic.
Our new Sunshine magazine, available online and in print, brought good news to our community during the winter season, with 3 editions communicating messages around vaccine efficacy, wellbeing advice and positive stories about research.
An incredible 87 people joined us for a walk on the day after Aplastic Anaemia Awareness Day, some remotely on our Together Walk and others in person in the Peak District, a great sign that the campaign we designed to connect people remotely during lockdown has potential to grow further with in-person events.
This year during the Super Rare campaign, we took advantage of a special opportunity offered to charities to run a digital ad campaign across various UK news websites including The Guardian, to tell the general public about our work to fund Covid-19 vaccine research for people with rare bone marrow failure. Our advert achieved 1.9million impressions and was clicked by 918 people.
## **Looking ahead**
The AAT will continue to build on the core activities outlined in the annual report, for the benefit of its patient and family communities.
2023 will be an important year for our Support and Outreach team, who will begin to develop a programme of thematic services based on unmet needs in the community.
It will be significant for the development of our evidence base, through the design and delivery of the first ever national community survey for people with AA and related rare bone marrow failures.
Page 6
## **The Aplastic Anaemia Trust**
## **Trustees' Report**
**The principles underpinning the AAT’s strategic objectives will be community-first ethos, collaborative working and organisational excellence.**
## **Risk management**
The Trustees have a duty to identify, assess and regularly scrutinise the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error. The Trustees have mapped significant risks that may have an adverse effect on the AAT’s charitable activities.
A robust risk management framework is in place and remains effective in enabling the Trustees to oversee and monitor strategic risks, reviewing progress against specific action plans quarterly.
## **Going Concern**
The Trustees consider there are no material uncertainties about the charitable company’s ability to continue as a going concern. The review of the financial position and future plans gives Trustees confidence that the charity remains a going concern for the foreseeable future.
## **Financial Review**
Unrestricted income for the year totalled £223,218 (2021: £222,766) and expenditure amounted to £132,267 (2021: £151,461) resulting in net income on unrestricted funds for the year of £90,951 (2021: £71,305). Expenditure has been reduced by £63,576 of research grant commitments overprovided from before the pandemic and no longer needed. In addition, restricted income of £9,971 was received in the year. Expenditure incurred and charged against restricted income funds amounted to £108,068 (2021: £123,474), leaving balances on restricted funds totalling £3,571 at 31 March 2022.
At the end of the year the charity had free, unrestricted reserves of £443,653.
## **Reserves Policy**
The Trustees have considered the charitable company’s position with regard to formulating a reserves policy, aligned with the organisation’s strategy moving forward.
Under its reserve policy the charitable company follows the following principles:
Ensure that it has an operating income reserve equivalent to approximately 12 months of operational costs of the charity plus a reasonable amount of investment funds to draw upon, in line with the strategy, to the minimum value of £200,000, approved by the trustees in the Reserves Policy in March 2022.
Ensure that the charitable company retains reasonable reserves to cover unforeseen emergency or other unexpected need for funds.
Given the above, the Trustees have allocated funds to a series of projects in 2023 which support the organisational strategy:
New clinical research projects Impact evaluation S&O team resource
Page 7
## **The Aplastic Anaemia Trust**
## **Trustees' Report**
## **Recruitment & appointment of Trustees**
When recruiting new Trustees, the Trust looks for individuals with skills and experience which are considered of value to the charity and which are not necessarily held by existing Trustees. Potential Trustees are interviewed by existing Trustees and, if appointed, are provided with a pack of information including, inter alia, a copy of the most recent annual report and financial statements, a copy of the charitable company’s Memorandum and Articles of Association and minutes of recent Trustee meetings. New Trustees then sign a declaration of willingness to act as a charity Trustee before being eligible to vote.
The Trustees are also Members of the charitable company.
## **Chief Executive**
The Trustees have delegated day-to-day management of the Trust’s affairs to Stevie Tyler, the AAT’s Chief Executive, during this financial period.
## **Research and Clinical Advisory Panel Members**
The RCAP members were confirmed in post in December 2021. They are not trustees but an advisory panel of experts reporting to the Board.
Chair - Prof. Ghulam Mufti Vice-Chair - Prof. Peter Hillmen Dr. Sujith Samarasinghe Dr. Dominic Culligan Dr. Josu de la Fuente Dr Austin Kulasekararaj Dr. Bethany Mitchell Prof. Rod Skinner Prof. John Snowden Dr. Sanjay Tewari Prof. Alan Warren Dr. Keith Wilson
## **Small companies provision statement**
The accounts are prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.
The annual report was approved by the trustees of the charity on 31 August 2022 and signed on their behalf by:
......................................... A Conquy Trustee
Page 8
## **The Aplastic Anaemia Trust**
## **Independent Examiner's Report to the trustees of The Aplastic Anaemia Trust**
I report to the charity trustees on my examination of the accounts of the charity for the year ended 31 March 2022 which are set out on pages 10 to 18.
## **Respective responsibilities of trustees and examiner**
As the company's trustees (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Charities and Trustee Investment (Scotland) Act 2005 ('the 2005 Act'), the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Companies Act 2006 ('the 2006 Act'). You are satisfied that the accounts of the company are not required by charity or company law to be audited and have chosen instead to have an independent examination.
Having satisfied myself that the accounts of the company are not required to be audited under Part 16 of the 2006 Act and eligible for independent examination, I report in respect of my examination of the company's accounts as carried out under section 44 (1) (c) of the 2005 Act and section 145 of the Charities Act 2011 (the '2011 Act'). In carrying out my examination I have followed the requirements of Regulation 11 of the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.
## **Independent examiner’s statement**
I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:
1. accounting records were not kept in respect of the charitable company as required by section 386 of the 2006 Act and Regulation 4 of the 2006 Accounts Regulations; or
2. the accounts do not accord with those records with the accounting requirements of Regulation 8 of the Charities Accounts (Scotland) Regulations 2006; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).
I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.
...................................... Mark Heaton FCCA FCIE DChA KM 1st Floor, Block C The Wharf Manchester Road Burnley Lancashire BB11 1JG
31 August 2022
Page 9
## **The Aplastic Anaemia Trust**
## **Statement of Financial Activities for the Year Ended 31 March 2022**
## **(Including Income and Expenditure Account and Statement of Total Recognised Gains and Losses)**
|**Note**
**Income from:**
Donations and legacies
3
Grants receivable
Fund-raising events
Other income
Investment income
5
Total income
**Expenditure on:**
Raising funds
6
Charitable activities
7
Total expenditure
Net income/(expenditure)
Net movement in funds
**Reconciliation of funds**
Total funds brought forward
Total funds carried forward
17|**Unrestricted**
**funds**
**£**
185,533
10,000
27,661
-
24
223,218
(23,345)
(108,922)
(132,267)
90,951
90,951
352,702
443,653|**Restricted**
**funds**
**£**
-
9,971
-
-
-
9,971
-
(108,068)
(108,068)
(98,097)
(98,097)
101,668
3,571|**Total**
**2022**
**£**
185,533
19,971
27,661
-
24
233,189
(23,345)
(216,990)
(240,335)
(7,146)
(7,146)
454,370
447,224|**Unrestricted**
**funds**
**£**
113,987
102,966
1,091
4,722
-
222,766
(3,186)
(148,275)
(151,461)
71,305
71,305
281,397
352,702|**Restricted**
**funds**
**£**
-
-
-
-
-
-
(21,851)
(101,623)
(123,474)
(123,474)
(123,474)
225,142
101,668|**Total**
**2021**
**£**
113,987
102,966
1,091
4,722
-|
|---|---|---|---|---|---|---|
|||||||222,766|
|||||||(25,037)
(249,898)|
|||||||(274,935)|
|||||||(52,169)|
|||||||(52,169)
506,539|
|||||||454,370|
All of the charity's activities derive from continuing operations during the above two periods. The funds breakdown for 2021 is shown in note 17.
Page 10
## **The Aplastic Anaemia Trust**
## **(Registration number: 05174065) Balance Sheet as at 31 March 2022**
|**Note**
**Current assets**
Debtors
13
Cash at bank and in hand
**Creditors: Amounts falling due within one year**
14
**Total assets less current liabilities**
**Creditors: Amounts falling due after more than one year**
15
**Net assets**
**Funds of the charity:**
**Restricted income funds**
Restricted funds
**Unrestricted income funds**
Unrestricted funds
**Total funds**
17|**2022**
**£**
131
607,334
607,465
(77,535)
529,930
(82,706)
447,224
3,571
443,653
447,224|**2021**
**£**
-
697,621|
|---|---|---|
|||697,621
(243,251)|
|||454,370
-|
|||454,370|
|||101,668
352,702|
|||454,370|
For the financial year ending 31 March 2022 the charity was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
- The members have not required the charity to obtain an audit of its accounts for the year in question in accordance with section 476. However, in accordance with section 44 of the Charities and Trustee Investment (Scotland) Act 2005, the accounts have been examined by an independant examiner whose report appears on page 12; and
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.
The financial statements on pages 10 to 18 were approved by the trustees, and authorised for issue on 31 August 2022 and signed on their behalf by:
......................................... A Conquy Trustee
Page 11
## **The Aplastic Anaemia Trust**
## **Notes to the Financial Statements for the Year Ended 31 March 2022**
## **1 Charity status**
The charity is limited by guarantee, incorporated in England, and consequently does not have share capital. Each of the trustees is liable to contribute an amount not exceeding £100 towards the assets of the charity in the event of liquidation.
The address of its registered office is: 1st Floor, Block C The Wharf Manchester Road Burnley Lancashire BB11 1JG
These financial statements were authorised for issue by the trustees on 31 August 2022.
## **2 Accounting policies**
## **Summary of significant accounting policies and key accounting estimates**
The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.
## **Statement of compliance**
The financial statements have been prepared under the historical cost convention, on a going concern basis, in accordance with the Charity Commissioners' "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland" (effective January 2019) ("the SORP (FRS 102)"), FRS 102, the Charities and Trustees Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006, the Charities Act 2011 and the Companies Act 2006.
## **Basis of preparation**
The Aplastic Anaemia Trust meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.
## **Going concern**
The trustees consider that there are no material uncertainties about the charity's ability to continue as a going concern nor any significant areas of uncertainty that affect the carrying value of assets held by the charity.
## **Exemption from preparing a cash flow statement**
The charity is exempt from preparing a cash flow statement.
## **Income**
All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of the income receivable can be measured reliably.
Page 12
## **The Aplastic Anaemia Trust**
## **Notes to the Financial Statements for the Year Ended 31 March 2022**
## _**Investment income**_
Dividends are recognised once the dividend has been declared and notification has been received of the dividend due.
## **Expenditure**
All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources.
## **Governance costs**
These include the costs attributable to the charity’s compliance with constitutional and statutory requirements.
## **Trade creditors**
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the charity does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.
Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.
## **Fund structure**
Unrestricted income funds are general funds that are available for use at the trustees's discretion in furtherance of the objectives of the charity.
Restricted income funds are those donated for use in a particular area or for specific purposes, the use of which is restricted to that area or purpose.
## **Pensions and other post retirement obligations**
The charity operates a defined contribution pension scheme which is a pension plan under which fixed contributions are paid into a pension fund and the charity has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.
Contributions to defined contribution plans are recognised in the Statement of Financial Activities when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.
## **3 Income from donations**
|Donations and legacies|**Total**
**2022**
**£**
185,533
185,533|**Total**
**2021**
**£**
113,987|
|---|---|---|
|||113,987|
Page 13
## **The Aplastic Anaemia Trust**
## **Notes to the Financial Statements for the Year Ended 31 March 2022**
## **4 Income from charitable activities**
|Grants receivable
**5**
**Investment income**
Interest receivable and similar income;
Interest receivable on bank deposits
**6**
**Expenditure on raising funds**
Raising funds
**7**
**Expenditure on charitable activities**
**Unrestricted**
**funds**
**Note**
**General**
**£**
Patient Information,
outreach & support
169,791
Research & grants
(63,576)
Governance costs
8
2,707
108,922|**Restricted**
**funds**
**£**
9,971
9,971
**Unrestricted**
**funds**
**General**
**£**
23,345
23,345
**Restricted**
**funds**
**£**
108,068
-
-
108,068|**Total**
**2022**
**£**
19,971
19,971
**Unrestricted**
**funds**
**General**
**£**
24
**Total**
**2022**
**£**
23,345
23,345
**Total**
**2022**
**£**
277,859
(63,576)
2,707
216,990|**Total**
**2021**
**£**
102,966|
|---|---|---|---|
||||102,966|
||||**Total**
**2022**
**£**
24|
||||**Total**
**2021**
**£**
25,037|
||||25,037|
||||**Total**
**2021**
**£**
184,501
63,453
1,944|
||||249,898|
Expenditure has been reduced by £63,576 relating to overstated research grant commitments made prior to the pandemic.
Page 14
## **The Aplastic Anaemia Trust**
## **Notes to the Financial Statements for the Year Ended 31 March 2022**
## **8 Analysis of governance and support costs**
## **Governance costs**
|Independent Examiner’s remuneration
Other governance costs|**Unrestricted**
**funds**
**General**
**£**
2,707
-
2,707|**Total**
**2022**
**£**
2,707
-
2,707|**Total**
**2021**
**£**
1,400
544|
|---|---|---|---|
||||1,944|
## **9 Trustees remuneration and expenses**
No trustees, nor any persons connected with them, have received any remuneration from the charity during the year.
No trustees have received any reimbursed expenses or any other benefits from the charity during the year.
## **10 Staff costs**
The aggregate payroll costs were as follows:
|**Staff costs during the year were:**
Wages and salaries
Social security costs
Pension costs|**2022**
**£**
101,668
9,642
3,524
114,834|**2021**
**£**
71,961
5,681
9,360|
|---|---|---|
|||87,002|
The monthly average number of persons (including senior management team) employed by the charity during the year expressed as full time equivalents was as follows:
|Charitable activites
The number of employees whose emoluments fell within the following bands
£60,001 - £70,000|**2022**
**No**
6
was:
**2022**
**No**
1|**2021**
**No**
5|
|---|---|---|
|||**2021**
**No**
1|
Page 15
## **The Aplastic Anaemia Trust**
## **Notes to the Financial Statements for the Year Ended 31 March 2022**
## **11 Independent examiner's remuneration**
|**11 Independent examiner's remuneration**|||
|---|---|---|
||**2022**|**2021**|
||**£**|**£**|
|Examination of the financial statements|2,707|1,400|
## **12 Taxation**
The charity is a registered charity and is therefore exempt from taxation.
## **13 Debtors**
|Other debtors
**14 Creditors: amounts falling due within one year**
Other taxation and social security
Research grant commitments
Pension scheme creditor
Accruals
**15 Creditors: amounts falling due after one year**
Research grant commitments|**2022**
**£**
131
**2022**
**£**
-
68,095
-
9,440
77,535
**2022**
**£**
82,706|**2021**
**£**
-|
|---|---|---|
|||**2021**
**£**
4,194
238,792
265
-|
|||243,251|
|||**2021**
**£**
-|
## **16 Pension and other schemes**
## **Defined contribution pension scheme**
The charity operates a defined contribution pension scheme. The pension cost charge for the year represents contributions payable by the charity to the scheme and amounted to £3,524 (2021 - £9,360).
Contributions totalling £Nil (2021 - £265) were payable to the scheme at the end of the year and are included in creditors.
Page 16
## **The Aplastic Anaemia Trust**
## **Notes to the Financial Statements for the Year Ended 31 March 2022**
|**17 Funds**
**Unrestricted funds**
General
**Restricted funds**
Marrowkidz Fund
Awards For All
**Total funds**
**Unrestricted funds**
General
**Restricted funds**
Marrowkidz Fund
Patient Information, Outreach &
Support Programme Fund
Emergency Response Covid-19
Fund
**Total funds**|**Balance at 1**
**April 2021**
**£**
352,702
352,702
101,668
-
101,668
454,370
**Balance at 1**
**April 2020**
**£**
281,397
281,397
158,621
34,386
32,135
225,142
506,539|**Incoming**
**resources**
**£**
223,218
223,218
-
9,971
9,971
233,189
**Incoming**
**resources**
**£**
222,766
222,766
-
-
-
-
222,766|**Resources**
**expended**
**£**
(132,267)
(132,267)
(101,668)
(6,400)
(108,068)
(240,335)
**Resources**
**expended**
**£**
(151,461)
(151,461)
(56,953)
(34,386)
(32,135)
(123,474)
(274,935)|**Balance at 31**
**March 2022**
**£**
443,653|
|---|---|---|---|---|
|||||443,653|
|||||-
3,571|
|||||3,571|
|||||447,224|
|||||**Balance at 31**
**March 2021**
**£**
352,702|
|||||352,702|
|||||101,668
-
-|
|||||101,668|
|||||454,370|
Page 17
## **The Aplastic Anaemia Trust**
## **Notes to the Financial Statements for the Year Ended 31 March 2022**
## **18 Analysis of net assets between funds**
|**18 Analysis of net assets between funds**||||
|---|---|---|---|
|Current assets
Current liabilities
Creditors over 1 year
Total net assets
Current assets
Current liabilities
Total net assets|**Unrestricted**
**funds**
**General**
**£**
603,894
(77,535)
(82,706)
443,653
**Unrestricted**
**funds**
**General**
**£**
595,953
(243,251)
352,702|**Restricted**
**funds**
**£**
3,571
-
-
3,571
**Restricted**
**funds**
**£**
101,668
-
101,668|**2022 Total**
**funds**
**£**
607,465
(77,535)
(82,706)|
||||447,224|
||||**2021 Total**
**funds**
**£**
697,621
(243,251)|
||||454,370|
Page 18